The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksE-therapeutics Regulatory News (ETX)

Share Price Information for E-therapeutics (ETX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 10.00
Bid: 9.50
Ask: 9.80
Change: 0.25 (2.66%)
Spread: 0.30 (3.158%)
Open: 9.20
High: 10.00
Low: 9.20
Prev. Close: 9.40
ETX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

22 Aug 2019 11:42

RNS Number : 9401J
e-Therapeutics plc
22 August 2019
 

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES

 

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii

 

e-Therapeutics PLC

 

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

Other (please specify):

 

3. Full name of person(s) subject to the notification obligation: iii

Rupert Labrum

4. Full name of shareholder(s)

(if different from 3.): iv

5. Date of the transaction and date on which the threshold is crossed or reached: v

16/08/2019

6. Date on which issuer notified:

20/08/2019

7. Threshold(s) that is/are crossed or reached: vi, vii

 

4.00%

 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type of shares

Situation previous to the triggering transaction

 

Resulting situation after the triggering transaction

 

if possible using

the ISIN CODE

Number of Shares

Number of Voting Rights

Number of shares

Number of voting rights

% of voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

 

 

GB00B2823H99

 

12015000

 

12015000

 

12015000

 

12015000

 

4.46%

 

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financial

Expiration

Exercise/

Number of voting

% of voting

instrument

date xiii

Conversion

rights that may be

rights

Period xiv

acquired if the

instrument is

exercised/

converted.

 

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financial instrument

Exercise price

Expiration date xvii

Exercise/ Conversion period xviii

Number of voting rights instrument refers to

% of voting rights

xix, xx

Nominal

Delta

 

Total (A+B+C)

Number of voting rights

Percentage of voting rights

1201500

4.46%

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: xxi

 

 

 

 

 

 

 

 

 

 

Proxy Voting:

10. Name of the proxy holder:

11. Number of voting rights proxy holder will cease to hold:

12. Date on which proxy holder will cease to hold voting rights:

 

 

13. Additional information:

14. Contact name:

Rupert Labrum

15. Contact telephone number:

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
HOLEAEPAAAKNEFF
Date   Source Headline
2nd Jan 20203:28 pmRNSDirector/PDMR Shareholding
8th Nov 201910:54 amRNSHolding(s) in Company
29th Oct 20194:10 pmRNSHolding(s) in Company
28th Oct 20192:36 pmRNSHolding(s) in Company
28th Oct 201912:05 pmRNSHolding(s) in Company
28th Oct 20198:00 amRNSHolding(s) in Company
7th Oct 20197:00 amRNSHalf-year Report
17th Sep 20194:41 pmRNSHolding(s) in Company
4th Sep 20192:05 pmRNSSecond Price Monitoring Extn
4th Sep 20192:00 pmRNSPrice Monitoring Extension
4th Sep 201911:05 amRNSSecond Price Monitoring Extn
4th Sep 201911:00 amRNSPrice Monitoring Extension
23rd Aug 201911:21 amRNSHolding(s) in Company
22nd Aug 201911:42 amRNSHolding(s) in Company
13th Aug 20197:00 amRNSe-therapeutics to work with top pharma company
1st Aug 20197:00 amRNSExtends Research Collaboration with Novo Nordisk
15th Jul 20192:06 pmRNSSecond Price Monitoring Extn
15th Jul 20192:00 pmRNSPrice Monitoring Extension
2nd Jul 20197:00 amRNSDirector/PDMR Shareholding
28th Jun 20192:06 pmRNSSecond Price Monitoring Extn
28th Jun 20192:00 pmRNSPrice Monitoring Extension
27th Jun 20193:17 pmRNSHolding(s) in Company
26th Jun 20194:41 pmRNSHolding(s) in Company
6th Jun 20193:58 pmRNSHolding(s) in Company
30th Apr 201911:21 amRNSResult of AGM
2nd Apr 20197:00 amRNSDirector/PDMR Shareholding
29th Mar 201910:00 amRNSDirector/PDMR Shareholding
20th Mar 201911:05 amRNSSecond Price Monitoring Extn
20th Mar 201911:00 amRNSPrice Monitoring Extension
14th Mar 201912:39 pmEQSEdison issues outlook on Jersey Electricity (JEL)
8th Mar 201910:30 amRNSNotice of Annual General Meeting and Annual Report
5th Mar 20193:51 pmEQSEdison issues update on e-Therapeutics (ETX)
5th Mar 20197:00 amRNSFull Year Results
20th Feb 20197:00 amRNSNotification of Full Year Results Date
3rd Jan 20199:00 amRNSDirector/PDMR Shareholding
12th Dec 20181:01 pmEQSEdison Investment Research Limited: Edison issues outlook on e-Therapeutics (ETX)
10th Dec 20187:00 amRNSResearch Collaboration Agreement with Novo Nordisk
6th Dec 201810:36 amEQSEdison Investment Research Limited: Edison issues update on e-Therapeutics (ETX)
6th Dec 20187:00 amRNSE-therapeutics and C4X Collaboration
29th Nov 20187:00 amRNSDrug Discovery Innovation Programme Presentation
12th Nov 201811:30 amRNSe-therapeutics to present at BioCentury Summit
5th Nov 20187:00 amRNSHolding(s) in Company
8th Oct 201810:42 amEQSEdison issues update on e-Therapeutics (ETX)
4th Oct 20187:00 amRNSInterim Results for six months ended 31 July 2018
17th Sep 201811:30 amRNSNotice of Interim Results
9th Aug 20187:00 amRNSDirector Shareholding
7th Aug 20187:00 amRNSDirector/PDMR Shareholding
3rd Jul 20182:08 pmRNSDirector/PDMR Shareholding
31st May 20182:13 pmRNSResults of Annual General Meeting
1st May 20187:00 amRNSCollaboration with C4X Discovery Holdings PLC

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.